STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.
💡 AI analysis provides alternative perspectives on current events